Tubulointerstitial Nephritis in ANCA-Associated Vasculitis as a Rare Adverse Effect of Adalimumab: A Case Report
Monitoring of renal function is strongly recommended in all patients treated with adalimumab. Early diagnosis of drug-induced tubulointerstitial nephritis due to vasculitis and immediate withdrawal of the offending drug are key to renal recovery and prevention from irreversible serious organ damage.
Authors
- M Mtir
- I. Mami (ORCID: https://orcid.org/0000-0002-8668-3636)
- Taieb Jomni
- Myriam Ayari (ORCID: https://orcid.org/0000-0001-7361-8248)
- Sarra Ben Azouz (ORCID: https://orcid.org/0000-0002-9628-265X)
- Hedi Douggui
- L. Raïs
Institutions
- Hôpital La Rabta (TN)
Publication Details
- Journal
- Current Drug Safety
- Published
- 2025-03-26
- DOI
- https://doi.org/10.2174/0115748863362460250220172535
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00